Stockscreener 앱 받기
2.76
5.46%
-0.17
전일 마감가:
$2.93
열려 있는:
$2.92
하루 거래량:
165.57K
Relative Volume:
0.98
시가총액:
$71.65M
수익:
-
순이익/손실:
$-94.11M
주가수익비율:
-0.4592
EPS:
-6.01
순현금흐름:
$-86.06M
1주 성능:
-19.24%
1개월 성능:
-45.69%
6개월 성능:
-66.46%
1년 성능:
-75.57%
1일 변동 폭
$2.76
$3.035
1주일 범위
$2.745
$3.71
52주 변동 폭
$2.745
$11.87
Adverum Biotechnologies Inc Stock (ADVM) Company Profile
명칭
Adverum Biotechnologies Inc
전화
(650) 649-1004
주소
100 CARDINAL WAY, REDWOOD CITY, CA
ADVM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ADVM
Adverum Biotechnologies Inc
|
2.76 | 71.65M | 0 | -94.11M | -86.06M | -6.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.09 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
559.01 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
594.73 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
230.31 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.84 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Adverum Biotechnologies Inc Stock (ADVM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-06-25 | 개시 | Oppenheimer | Outperform |
| 2024-04-30 | 개시 | H.C. Wainwright | Buy |
| 2022-07-07 | 업그레이드 | Truist | Hold → Buy |
| 2021-07-23 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2021-05-03 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2021-04-29 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2021-04-29 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-04-29 | 다운그레이드 | Truist | Buy → Hold |
| 2020-12-16 | 개시 | UBS | Neutral |
| 2020-11-12 | 업그레이드 | Raymond James | Underperform → Mkt Perform |
| 2020-06-26 | 다운그레이드 | Raymond James | Mkt Perform → Underperform |
| 2020-05-13 | 개시 | RBC Capital Mkts | Outperform |
| 2020-05-05 | 업그레이드 | SunTrust | Hold → Buy |
| 2020-04-28 | 개시 | Goldman | Buy |
| 2020-03-16 | 개시 | SVB Leerink | Outperform |
| 2020-02-10 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2020-02-10 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2019-10-15 | 재확인 | Chardan Capital Markets | Neutral |
| 2019-09-13 | 재확인 | Chardan Capital Markets | Neutral |
| 2019-06-14 | 재개 | Raymond James | Mkt Perform |
| 2018-11-02 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2018-11-02 | 다운그레이드 | SunTrust | Buy → Hold |
| 2018-09-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-08-30 | 개시 | SunTrust | Buy |
| 2018-02-15 | 재개 | Piper Jaffray | Overweight |
| 2017-10-12 | 개시 | Raymond James | Outperform |
모두보기
Adverum Biotechnologies Inc 주식(ADVM)의 최신 뉴스
Bronstein, Gewirtz & Grossman, LLC Encourages Adverum Biotechnologies, Inc. (ADVM) Stockholders to Inquire about Securities Investigation - markets.businessinsider.com
Truist Removes $40 Price Target on Adverum Biotechnologies, Cites Share Volatility, Keeps Buy Rating - marketscreener.com
Bronstein, Gewirtz & Grossman, LLC Encourages Adverum Biotechnologies, Inc. (ADVM) Investors to Inquire about Securities Investigation - markets.businessinsider.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Adverum Biotechnologies, Inc. (ADVM) And Encourages Investors to Reach Out - markets.businessinsider.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Adverum Biotechnologies, Inc. (ADVM) And Encourages Stockholders to Reach Out - markets.businessinsider.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc. - GlobeNewswire Inc.
Intuit To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Thursday - Benzinga
Bronstein, Gewirtz & Grossman, LLC Is Investigating Adverum Biotechnologies, Inc. (ADVM) And Encourages Stockholders to Connect - markets.businessinsider.com
Press Release Distribution & PR Platform - ACCESS Newswire
RBC Cuts Price Target on Adverum Biotechnologies to $5 From $10, Keeps Sector Perform, Speculative Risk - marketscreener.com
Adverum Biotechnologies Reports 2024 Financial Results and Pipeline Progress - TipRanks
Adverum Biotechnologies: Q4 Earnings Snapshot - CT Insider
Adverum Biotechnologies, Inc. (ADVM) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - markets.businessinsider.com
ADVM Investors Have Opportunity to Join Adverum Biotechnologies, Inc. Fraud Investigation with the Schall Law Firm - PR Newswire
Adverum Biotechnologies Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Adverum Biotechnologies Reports Fourth Quarter and Full - GlobeNewswire
Adverum Advances Gene Therapy Pipeline Despite Wider Losses: Key Q4 Developments Revealed - Stock Titan
Adverum Biotechnologies, Inc. SEC 10-K Report - TradingView
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc.ADVM - PR Newswire
Avalanche Biotechnologies Announces Executive Changes - MarketScreener
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - MarketScreener
Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Adverum Biotech Grants 30,000 Share Options to New Executive: Key Details - Stock Titan
Adverum biotechnologies sees $147k stock purchase by major shareholder - Investing.com Australia
Adverum Biotechnologies, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your RightsADVM - ACCESS Newswire
Adverum Biotechnologies Inc expected to post a loss of $1.36 a shareEarnings Preview - TradingView
Adverum Biotechnologies to Participate in the 2025 RBC Capital Markets Ophthalmology Virtual Conference - The Manila Times
Exclusive: Adverum Gene Therapy Updates Coming at Major Ophthalmology Conference - Stock Titan
Adverum biotechnologies investor Leonard Braden Michael buys $188,930 in stock By Investing.com - Investing.com Australia
Adverum biotechnologies sees insider purchase totaling $587,574 By Investing.com - Investing.com Canada
Adverum biotechnologies sees insider purchase totaling $587,574 - Investing.com
Adverum Biotechnologies (ADVM) to Release Earnings on Monday - Defense World
2025 Market Prospects of Adeno-Associated Virus Vectors in Gene Therapy Pipeline: 200 Pipeline Drugs and the Strategic Workings of 180+ Companies - GlobeNewswire Inc.
Adverum Biotechnologies Initiates ARTEMIS Phase 3 Study Evaluating Ixo-vec for Wet AMD - Marketscreener.com
Adverum launches phase 3 trial for wet AMD gene therapy By Investing.com - Investing.com UK
Can This One-Time Gene Therapy Revolutionize Wet AMD Treatment? Adverum's Phase 3 Trial Begins - StockTitan
Adverum Biotechnologies initiates ARTEMIS study - TipRanks
Adverum biotechnologies sees $1.44 million stock purchase by major shareholder - Investing.com Australia
How Adverum is Attracting Talent: New Employees Receive $186,000 in Equity Grants - StockTitan
Adverum Biotechnologies Inc (ADVM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.77%
0.11%
자본화:
|
볼륨(24시간):